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A B S T R A C T
No adequate treatment is available for painful urinary bladder disorders such as interstitial cystitis/bladder pain
syndrome, and the identification of new urological therapeutic targets is an unmet need. The sigma-1 receptor
(σ1-R) modulates somatic pain, but its role in painful urological disorders is unexplored. The urothelium ex-
presses many receptors typical of primary sensory neurons (e.g. TRPV1, TRPA1 and P2X3) and high levels of σ1-
R have been found in these neurons; we therefore hypothesized that σ1-R may also be expressed in the ur-
othelium and may have functional relevance in this tissue. With western blotting and immunohistochemical
methods, we detected σ1-R in the urinary bladder in wild-type (WT) but not in σ1-R-knockout (σ1-KO) mice.
Interestingly, σ1-R was located in the bladder urothelium not only in mouse, but also in human bladder sections.
The severity of histopathological (edema, hemorrhage and urothelial desquamation) and biochemical alterations
(enhanced myeloperoxidase activity and phosphorylation of extracellular regulated kinases 1/2 [pERK1/2]) that
characterize cyclophosphamide-induced cystitis was lower in σ1-KO than in WT mice. Moreover, cyclopho-
sphamide-induced pain behaviors and referred mechanical hyperalgesia were dose-dependently reduced by σ1-R
antagonists (BD-1063, NE-100 and S1RA) in WT but not in σ1-KO mice. In contrast, the analgesic effect of
morphine was greater in σ1-KO than in WT mice. Together these findings suggest that σ1-R plays a functional role
in the mechanisms underlying cyclophosphamide-induced cystitis, and modulates morphine analgesia against
urological pain. Therefore, σ1-R may represent a new drug target for urinary bladder disorders.
1. Introduction
Different bladder pathologies such as interstitial cystitis/bladder pain
syndrome (IC/BPS) and bladder cancer can cause severe pain and
markedly affect patients’ quality of life [1,2]. In particular, IC/BPS
courses with intense suprapubic/pelvic pain together with increased ur-
inary frequency and urgency, and can be manifested by cystoscopic ab-
normalities including petechial hemorrhages or ulcers and urothelial loss
[3]. No effective treatment has been found to date, and achieving ac-
ceptable control of the symptoms generally requires trials with multiple
therapeutic options [4]. The identification of new drug targets of poten-
tial use in the treatment of bladder pain may thus provide new treatment
opportunities for IC/BPS and other painful urologic pathologies.
The sigma-1 receptor (σ1-R) is a ligand-operated chaperone [5]. It
has been cloned; its sequence is 90 % identical between humans and
mice [6], and it does not resemble any other known mammalian protein
– a feature that underscores its uniqueness [7]. σ1-R modulates different
types of somatic pain, including inflammatory and neuropathic pain
[8–11], but its role in painful urological disorders remains entirely
unexplored. The urothelium expresses many receptors typical of pri-
mary sensory neurons (e.g. TRPV1, TRPA1, P2X3, etc.) [12], and high
levels of σ1-R are detected in these neurons [13–15]; consequently, we
hypothesized that σ1-R may also be expressed in the urothelium. To test
this hypothesis, we carried out immunohistochemical studies in human
and mouse urinary bladder sections. We found σ1-R in the urothelium of
both species (see Results), and therefore decided to test its functional
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relevance in a mouse model of cystitis.
Among the many animal models of cystitis that have been devel-
oped [16,17], we choose the cyclophosphamide-induced cystitis model
because it is one of the better known and most frequently used models
of bladder inflammation and pain. Cyclophosphamide-induced cystitis
produces several histopathological alterations in the urinary bladder,
including edema, hemorrhage and urothelial desquamation [18,19].
Moreover, it results in the activation (phosphorylation) of extracellular
signal-regulated kinases 1 and 2 (pERK1/2) and in neutrophil infiltra-
tion, which is manifested by an increase in myeloperoxidase (MPO)
activity [18–20]. Therefore, to test the functional relevance of bladder
σ1-R, we first compared cyclophosphamide-induced bladder alterations
in wild-type (WT) and σ1-R knockout (σ1-KO) mice. In addition, be-
cause cyclophosphamide produces spontaneous pain behaviors and
mechanical hyperalgesia referred to the abdominal wall [21–25], we
compared these pain manifestations in animals of both genotypes. Fi-
nally, we tested whether σ1-R might offer a new drug target for the
treatment of painful urinary bladder disorders by evaluating the effects
of several selective σ1-R antagonists (BD-1063, NE-100 and S1RA) [7]
on the spontaneous pain and referred mechanical hyperalgesia induced
by cyclophosphamide in mice, and their effects on one of the bio-
chemical alterations induced in the bladder by cyclophosphamide, i.e.
the increase in MPO activity. In all cases, to confirm that σ1-R an-
tagonists were acting on their target, we tested them in both WT and σ1-
KO mice; furthermore, we compared the effect of σ1-R antagonists with
that of morphine as an analgesic control drug.
2. Methods
2.1. Animals and drugs
Experiments were done in WT (Charles River, Barcelona, Spain) and
homozygous σ1-KO (Esteve Pharmaceuticals, Barcelona, Spain) CD-1
mice weighing 25–30 g. The σ1-KO mice were generated on a CD-1
background as described previously [26]. Because IC/BPS is more
common in women than in men [27], we choose female mice to per-
form the experiments. Animals were acclimated in our animal facilities
for at least 1 week before testing, and were housed in colony cages in
temperature- and light-controlled rooms (22±1 °C, lights on at 8:00
AM and off at 8:00 PM, air replacement every 20 min). A standard
laboratory diet (Harlan Teklad Research Diets, Madison, WI, USA) and
tap water were available ad libitum until the beginning of the experi-
ments. Animals were tested at random times throughout the estrous
cycle. Testing took place during the light phase (from 9:00 AM to 3:00
PM). Mice were handled in accordance with the European Communities
Council directive 2010/63, and all procedures were approved by the
Research Ethics Committee of the University of Granada. In order to
minimize the number of animals used in the study, when possible, the
same animals were used for behavioral studies and to obtain urinary
bladders for in vitro studies.
We used the following selective σ1-R antagonists: BD-1063 (1-[2-
(3,4-dichlorophenyl)ethyl]-4-methylpiperazine dihydrochloride), sup-
plied by Tocris Cookson Ltd. (Bristol, UK); NE-100 (N,N-dipropyl-2-[4-
methoxy-3-(2-phenylethoxy)phenyl]ethylamine hydrochloride), syn-
thesized as reported previously [28]; and S1RA (4-[2-[[5-methyl-1-(2-
naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl] morpholine hydrochloride)
[29], supplied by Esteve Pharmaceuticals. Morphine hydrochloride
(General Directorate of Pharmacy and Drugs, Spanish Ministry of
Health, Madrid, Spain) was used as the opioid agonist drug. Each drug
was dissolved in sterile physiological saline. Drug solutions were pre-
pared immediately before the start of the experiments, and 5 ml/kg of
the drug solution or its solvent was injected subcutaneously (s.c.) into
the interscapular area.
Cyclophosphamide (Sigma-Aldrich, Madrid, Spain), which was used
to induce cystitis, was dissolved in saline and injected intraperitoneally
(i.p.) at a volume of 10 ml/kg. The same volume of solvent was injected
in control animals. Different doses of cyclophosphamide were used
during the study (10, 30, 100, 200 and 300 mg/kg).
In all cases the researchers who performed the experiments were
unaware of the mouse genotype and were blinded to the treatment
received by each animal.
2.2. Human and mouse urinary bladder immunohistochemistry
Formalin-fixed, paraffin-embedded adult human normal bladder
sections (5 μm thick) mounted on glass slides were obtained from
BioChain Institute (Newark, CA, USA, lot number B507075). Mouse
urinary bladder sections were obtained from control and cyclopho-
sphamide-treated WT and σ1-KO mice, and were processed according to
standard procedures [18,19]. Animals were anesthetized with iso-
fluorane (IsoVet®, B. Braun, Barcelona, Spain) and perfused in-
tracardially with 20 ml saline followed by 30 ml 3.7–4.0 % for-
maldehyde buffered to pH 7.0 (Panreac Quimica SLU, Barcelona,
Spain). After perfusion, the mouse bladder was removed and the whole
organ was post-fixed in 3.7–4.0 % formaldehyde for 24 h. Then the
bladders were dehydrated in solutions of increasing ethanol con-
centrations, followed by immersion in xylene, and were then embedded
in paraffin. Tissue sections (5 μm thick) were obtained with a micro-
tome (Microm HM325, Thermo Scientific, Watham, MA, USA) and
mounted on poly-L-lisine-coated glass slides.
Human and mouse urinary bladder sections were deparaffinized and
hydrated in preparation for antigenic unmasking by heat treatment
(steam at 95 °C for 20 min) in sodium citrate 10 mM buffer at pH 8.0
(Master Diagnóstica, Granada, Spain), followed by cooling in distilled
water at room temperature for 10 min. Then endogenous peroxidase
activity was blocked with 3 % (vol/vol) H2O2 in methanol for 15 min,
followed by successive washes (5 min each) in distilled water and TBS-
Tween 20 buffer (Tris buffered saline, pH 7.4, Thermo Scientific) with
0.1 % Tween 20.
For σ1-R detection, the Ultra Vision Quanto peroxidase kit (TL-060-
QHD, Thermo Scientific) was used. Nonspecific staining was blocked
with Quanto Ultra V Block for 8 min at room temperature. Then sam-
ples were incubated for 30 min at room temperature with a σ1-R mouse
monoclonal primary antibody (sc-137075, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at 1:400 dilution in TBS-Tween 20 buffer. After
three washes (10 min each) with TBS-Tween 20 buffer, samples were
incubated with Quanto amplifier for 10 min, rinsed in TBS-Tween 20 (3
washes of 5 min each), and then incubated with Quanto HRP (horse-
radish peroxidase) polymer for 10 min at room temperature. After 3
washes (5 min each) with TBS-Tween 20, the peroxidase reaction was
visualized using 3, 3′-diaminobenzidine with the ImmPACT DAB
Peroxidase Substrate Kit (SK-4105, Vector Laboratories, Burlingame,
CA, USA). Briefly, bladder sections were incubated for 20 s at room
temperature with the reagent under dim light conditions, followed
immediately by two washes of 5 min each with distilled water. Then
samples were counterstained (2 min) in Mayer’s hematoxylin, and were
washed with slightly alkalinized water for 5 min, followed by dehy-
dration by rapid immersion (seconds) in solutions of increasing ethanol
concentrations and 3 rapid washes in xylene. Finally, a drop of Vitro-
Clud mounting medium (Deltalab, Barcelona, Spain) and a coverslip
were place over the sample. Negative controls for σ1-R detection were
obtained by omitting the primary antibody, and all control assays in-
dicated the absence of immunoreactivity. Images were acquired with a
Nikon Eclipse 50i microscope equipped with a DS-Ri1 camera (Nikon
Instruments Europe BV, Amsterdam, Netherlands).
2.3. Bladder histopathology
For histopathological studies three different histological alterations
(urinary bladder edema, hemorrhage and urothelial desquamation)
indicative of cyclophosphamide-induced cystitis were analyzed, ac-
cording to previously described methods [18,19], in bladder sections
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obtained from WT and σ1-KO mice.
A morphometric analysis of each hematoxylin–eosin-stained section
was performed with ImageJ software (http://rsb.info.nih.gov/ij/index.
html), and the edematous area located in the lamina propria (between
the urothelium and muscularis) was normalized with respect to the
total area of the bladder section. The numbers of hemorrhagic foci and
areas of urothelial desquamation were also counted in each section. All
images were acquired with an Olympus BX51 microscope.
2.4. Western blotting
Experiments were performed as previously described in detail
[9,15], with some modifications. The bladders were carefully removed
from control and cyclophosphamide-treated WT and σ1-KO mice (at 1, 3
or 5 h after the injection of cyclophosphamide 300 mg/kg i.p.), frozen
immediately in liquid nitrogen, and stored at −80 °C. Bladders were
thawed, finely minced with spring scissors, and homogenized in buffer
(RIPA buffer with 0.5 % protease inhibitor cocktail and 1 % phospha-
tase inhibitor cocktail-2, all from Sigma-Aldrich). Then homogenates
from three bladders were mixed and centrifuged at 1000 g for 5 min to
decant large remains. Protein concentration in the supernatants was
measured with the Bradford assay, and these supernatants were used
for western blot analyses.
Equal amounts of protein (24 μg for ERK and 30 μg for σ1-R) were
fractionated on 12 % (wt/vol) SDS-polyacrylamide gels and electro-
phoretically transferred to nitrocellulose membranes (Bio-Rad, Madrid,
Spain). The membranes were incubated for 1 h at room temperature in
blocking buffer containing 5 % dry skim milk in TBS-Tween 20, and
were incubated overnight at 4 °C with a rabbit polyclonal antibody
recognizing total ERK1/2 (M-5670, Sigma-Aldrich) at 1:40 000 dilu-
tion, a rabbit monoclonal antibody recognizing diphosphorylated ERKs
1 and 2 (pERK1/2) (4370S, Cell Signaling Technology, Danvers, MA,
USA) at 1:2000, or with a goat polyclonal antibody recognizing σ1-R
(sc-22948, Santa Cruz Biotechnology, Heidelberg, Germany) at 1:250.
To control for equal protein loading, rabbit polyclonal anti-glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) antibody was used at
1:40000 or 1:80000 depending on the experiment (G9545, Sigma-
Aldrich). All primary antibodies were diluted in TBS-Tween 20 buffer
containing 0.5 % dry skim milk. When the primary antibody incubation
period ended, the blots were washed 3 times for 10 min each with TBS-
Tween 20 buffer and then incubated for 1 h at room temperature with
horseradish peroxidase-conjugated goat anti-rabbit IgG or donkey anti-
goat IgG (both from Sigma-Aldrich), diluted at 1:2000 and 1:2500,
respectively, in TBS-Tween 20 buffer containing 0.5 % dry skim milk.
Then the membranes were washed with TBS-Tween 20 buffer 6 times
for 10 min each, and the peroxidase reaction was revealed with an
enhanced chemiluminescence method (ECL Prime Western Blotting
Detection Reagents, Amersham Biosciences, Buckinghamshire, UK) ac-
cording to the manufacturer’s instructions. Chemiluminescence was
detected with a LAS 3000 Image Analyzer System (Fujifilm, Tokyo,
Japan). Densitometric analysis of the immunoreactive bands was done
with Quantity One software (Bio-Rad) and normalized with respect to
the intensity of the corresponding GAPDH immunoreactive bands.
2.5. Myeloperoxidase activity
Changes in MPO activity represent a reliable index of poly-
morphonuclear leukocyte infiltration [30]. Therefore, 5 h after the in-
jection of cyclophosphamide, the urinary bladder of WT and σ1-KO
mice was dissected out, finely minced with spring scissors, and pro-
cessed as previously described to measure MPO activity [30]. Briefly,
minced urinary bladder samples were homogenized in 0.4 ml phos-
phate buffer (50 mM, pH 6.0) containing 0.5 % hexadecyl-
trimethylammonium bromide (HTAB, Sigma-Aldrich). The homo-
genates were freeze-thawed three times and centrifuged (6000 g, 10
min) to collect the supernatant, which was used for MPO activity assays
adapted to a 96-well plate format. Briefly, 50 μl of supernatant or
human neutrophil MPO standard (Sigma-Aldrich) was added to a 96-
well plate. The reaction was initiated by adding 150 μl phosphate buffer
containing 0.167 mg/ml o-dianisidine (Sigma-Aldrich) and 0.0005 %
hydrogen peroxide (Sigma-Aldrich), and absorption was measured 5
min later at 450 nm (Microplate Spectrophotometer PowerWave X,
BioTek Instruments, Winooski, VT, USA).
In some experiments, WT and σ1-KO mice were treated with cy-
clophosphamide (300 mg/kg i.p.), and 2 h later were given a dose (s.c.)
of a σ1-R antagonist (BD-1063, NE-100 or S1RA) or morphine. After 3 h
(i.e., 5 h after cyclophosphamide injection) the urinary bladder was
dissected out and MPO activity was measured according to the proce-
dures described above.
2.6. Cyclophosphamide-evoked visceral pain and referred hyperalgesia
Spontaneous pain-related behaviors and referred mechanical hyper-
algesia induced by cyclophosphamide were tested with a previously
described protocol [23–25], with small modifications [21,22]. Mice were
housed in individual transparent plastic boxes (7 × 7 × 13 cm) on an
elevated platform with a wire mesh floor, and with small mirrors behind
and below the chambers to facilitate observation. After a 40-min habi-
tuation period, the animals were removed from the compartments and
the cyclophosphamide solution (or its solvent) was injected. The animals
were immediately returned to the compartment, where they were ob-
served for 2 min every half-hour during a 4-h observation period after
cyclophosphamide injection. The recorded pain-related behaviors were
coded according to the following scale: 0 = normal, 1 = piloerection, 2
= marked piloerection, 3 = labored breathing, 4 = licking the ab-
domen, and 5 = stretching and contracting the abdomen [24]. If more
than one of these behaviors were noted in a given observation period, the
sum of the points for each different type of behavior was recorded; i.e., if
one abdominal licking (4 points) and two stretching and contraction (5
points each) episodes occurred during a given observation period, the
final score was 9 instead of 14 points. An overall score was obtained by
summing the scores for each time point. At the end of the 4-h observation
period, referred hyperalgesia was determined by measuring the with-
drawal response to a punctate mechanical stimulus on the abdomen.
Forces ranging from 0.02 to 2 g (0.19–19.6 mN) were applied to the
abdomen with a series of calibrated von Frey filaments (Touch-Test
Sensory Evaluators; North Coast Medical Inc., Gilroy, CA, USA) using the
up–down paradigm [31]. The perianal area and external genitalia were
avoided, and stimulation was applied to the lower and mid-abdomen as
reported previously [32]. The filaments were applied three times for 2–3
s each, with between-application intervals of 5 s. Testing was initiated
with the 0.4 g (3.92 mN) von Frey filament (i.e., the middle of the range).
In each consecutive test, if there was no response to the filament, a
stronger stimulus was then selected; if there was a positive response, a
weaker one was then used. The response to the filament was considered
positive if immediate licking or scratching at the application site, sharp
retraction of the abdomen, or jumping was observed.
To evaluate the effect of the drugs on cyclophosphamide-induced
visceral pain, we tested the effects of σ1-R antagonists and morphine, as
control drug, on the pain behavioral score and referred hyperalgesia.
Different doses of BD-1063 (16–64 mg/kg), S1RA (32–128 mg/kg), NE-
100 (16–64 mg/kg), morphine (1–8 mg/kg) or their solvent were ad-
ministered s.c. 2 h after the i.p. injection of cyclophosphamide, and the
pain behavioral score was recorded for 2 min every 30 min during 2 h
as described above. To test the effects of the drugs on pain-related
behaviors, a dose of 300 mg/kg cyclophosphamide was administered.
This dose of cyclophosphamide was selected because it was the lowest
one that produced maximum pain scores in WT mice (see Results,
Fig. 6A), and therefore offered an optimal window to observe any re-
ductions in this response.
In separate experiments we tested the effect of the same doses of σ1-
R antagonists and the control drug on mechanical hyperalgesia induced
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by cyclophosphamide and referred to the abdominal wall. A cyclo-
phosphamide dose of 100 mg/kg was selected for these experiments
because it produced maximal reductions in the mechanical threshold
for referred hyperalgesia in both WT and σ1-KO mice (see Results,
Fig. 8). In these experiments, the drug under study or its solvent was
injected s.c. 2 h after the i.p. administration of cyclophosphamide, and
2 h later (i.e., 4 h after cyclophosphamide injection) the responses to
abdominal stimulation were tested with von Frey filaments (up–down
method).
The experimenter who evaluated the behavioral responses was
blinded to the treatment and genotype of all experimental mice. In all
cases, experiments in WT or σ1-KO groups, solvent- or cyclopho-
sphamide-treated groups, and saline- or drug-treated groups were run
in parallel. Each animal was used only once and received a single
concentration of cyclophosphamide (or its solvent) and a single dose of
one drug (or its solvent).
2.7. Statistical analysis
The degree of referred hyperalgesia, expressed as the mechanical
threshold that produced 50 % of the responses, was calculated with Up-
Down Reader software [33]. When several means were compared,
statistical analysis was done with one-way or two-way analysis of
variance (ANOVA) depending on the experiment, followed by Bonfer-
roni’s post-hoc test. When two means were compared, Student’s t test
for unpaired values was used. The differences between values after ei-
ther ANOVA, Bonferroni’s or Student’s t test were considered significant
when the p value was below 0.05. All statistical analyses were done
with the SigmaPlot 12.0 program (Systat Software Inc., San Jose, CA,
USA).
3. Results
3.1. Expression of σ1-R in human and mouse urinary bladder
To determine the presence and localization of σ1-R in the urinary
bladder, we used immunostaining for σ1-R in bladder sections of mouse
and human origin. Immunohistochemical experiments in WT mouse
urinary bladder sections detected σ1-R immunoreactivity in the ur-
othelium. Immunostaining was distributed throughout the cytoplasm of
the different layers of urothelial cells (Fig. 1A). The specificity of im-
munostaining was demonstrated in two ways. First, we performed the
same experiments in urinary bladder sections from σ1-KO mice and
found no immunostaining (Fig. 1B), which indicated that the σ1-R an-
tibody used here reacted exclusively with σ1-R. Moreover, no σ1-R
immunoreactivity was found when urinary bladder sections from WT
mice were incubated with only the secondary antibody (i.e. the primary
σ1-R antibody was omitted) (data not shown).
Experiments in human urinary bladder sections showed σ1-R im-
munostaining in the same types of urothelial cells as in mouse bladder
sections (compare Figs. 1C and 1A). No immunostaining was detected
in human urinary bladder sections when the σ1-R primary antibody was
omitted (Fig. 1D).
To study whether cyclophosphamide treatment modified the ex-
pression of urinary bladder σ1-R, we performed western blot experi-
ments in bladder homogenates obtained from control mice and mice
treated with a high dose of cyclophosphamide (300 mg/kg i.p.) before
the bladders were removed. Western blot experiments with the σ1-R
antibody identified a band with a molecular weight slightly higher than
25 kDa in the urinary bladder of control WT mice (Fig. 2A). The
bladders of cyclophosphamide-treated WT mice also showed similar σ1-
R bands (Fig. 2A). When σ1-R band intensity was measured, it was
found that cyclophosphamide treatment did not affect σ1-R expression
in the urinary bladder of WT mice at any time point evaluated (Fig. 2B).
Similar experiments were performed in σ1-KO mouse urinary
bladder homogenates, but no σ1-R bands were found in either naïve or
cyclophosphamide-treated animals (Figs. 2A and 2B). As expected, the
loading control band (GAPDH) was expressed similarly in WT and σ1-
KO mice and in both experimental conditions (control and cyclopho-
sphamide-treated animals) (Fig. 2A), which indicated that the differ-
ences in σ1-R expression between WT and σ1-KO mice were not due to
experimental artefact.
In summary, we found that σ1-R was expressed in the urothelium of
both the human and mouse urinary bladder, and that cyclopho-
sphamide treatment in mice did not modify σ1-R expression in this
tissue.
3.2. Cyclophosphamide-induced enhancement of myeloperoxidase activity
and pERK1/2 expression in WT and σ1-KO mice
To identify the functional relevance of urinary bladder σ1-R, we
compared the characteristics of two different biochemical alterations
induced by cyclophosphamide in the bladder of WT and σ1-KO mice.
Cyclophosphamide treatment (10–300 mg/kg i.p.) produced a dose-
dependent increase in MPO activity in the urinary bladder of WT mice
(Fig. 3). Cyclophosphamide treatment also increases MPO activity in
the bladder of σ1-KO animals, but the increase was significantly lower
in these animals than in WT mice (Fig. 3). The maximum difference in
the effect of cyclophosphamide between WT and σ1-KO mice was ob-
served at 300 mg/kg (Fig. 3); therefore, this dose of cyclophosphamide
was chosen for subsequent experiments.
We also compared cyclophosphamide-induced pERK1/2 expression
in WT and σ1-KO mice as an additional marker of the functional role of
urinary bladder σ1-R. As expected, western blot experiments showed
that cyclophosphamide administration did not change bladder ERK1/2
levels in either WT or σ1-KO mice (Fig. 4A), but produced a time-de-
pendent increase in pERK1/2 expression in the bladder, particularly in
WT mice (Fig. 4B). When pERK1/2 levels were quantified, it was found
that the cyclophosphamide-induced increase in pERK1/2 levels was
significantly higher in WT than in σ1-KO animals at 3 and 5 h after drug
administration (Fig. 4C).
In summary, the two biochemical alterations (increases in MPO and
pERK1/2) induced by cyclophosphamide treatment in the urinary
bladder were attenuated in σ1-KO mice compared to WT mice.
3.3. Cyclophosphamide-induced changes in urinary bladder histology in WT
and σ1-KO mice
Hematoxylin–eosin staining in urinary bladder sections from control
WT mice showed a normal appearance, with the different layers
(muscularis, lamina propria and urothelium) being easily identifiable
(Fig. 5A, left panel). The appearance of control WT mice sections was
indistinguishable from that of control σ1-KO mice.
Cyclophosphamide treatment produced marked histological altera-
tions in the bladder of WT mice (at 5 h), with edema localized in the
lamina propria (between the urothelium and muscularis), which was
accompanied by areas of urothelial desquamation and hemorrhagic foci
(Figs. 5A, central panel and 5C, left panel). Cyclophosphamide-induced
histological alterations were attenuated in σ1-KO mice (Fig. 5A, right
panel). In particular, when the main manifestations of cystitis were
quantified, it was found that σ1-KO mouse urinary bladders showed a
reduction in the area affected by edema (Fig. 5B), as well as fewer areas
of urothelial desquamation and fewer hemorrhagic foci (Fig. 5C, right
panel).
3.4. Effect of genetic and pharmacological blockade of σ1-R on
cyclophosphamide-induced pain and referred mechanical hyperalgesia.
Comparison with morphine
Cyclophosphamide treatment produced pain behaviors in a dose-
dependent manner in both WT and σ1-KO animals (Fig. 6A). However,
the pain behavioral score was higher in WT than in σ1-KO animals, and
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was significantly higher in WT animals at doses of 30 mg/kg and
greater. In both groups of animals the highest pain behavioral scores
were seen at the highest dose of cyclophosphamide tested (300 mg/kg),
but the score was significantly lower in σ1-KO (20.33± 0.59) than in
WT (34.83±2.56) mice (Fig. 6A).
When the time course of pain induced by the highest dose of cy-
clophosphamide tested (300 mg/kg i.p.) was analyzed, it was found
that cyclophosphamide injection produced a progressive increase in the
pain behavioral score after longer times, and the differences with re-
spect to solvent-treated animals became significant after 90 min
(Fig. 6B). Cyclophosphamide-induced pain also occurred in σ1-KO mice,
and reached a peak at 120 min. After this time the behavioral score in
σ1-KO mice showed no further increase, and remained significantly
lower than in WT animals (Fig. 6B).
Because the maximum pain behavioral score was seen in animals
treated with 300 mg/kg cyclophosphamide i.p. (Fig. 6A), this dose was
chosen to test the effects of σ1 antagonists on cyclophosphamide-in-
duced pain. All σ1 antagonists tested (BD-1063, S1RA and NE-100),
injected 120 min after cyclophosphamide (i.e. when pain behavior was
clearly established (Fig. 6B), produced a dose-dependent decrease in
the pain behavioral score in WT animals, but no change in σ1-KO mice
(Fig. 7A). None of the σ1 antagonists abolished pain-related behaviors
in WT mice; however, at the highest doses tested, all of them reduced
the number of behaviors in WT mice to the same number observed in
cyclophosphamide-treated σ1-KO mice (Fig. 7A). In contrast, the s.c.
administration of morphine (1–8 mg/kg) dose-dependently reduced the
pain behavioral score elicited by cyclophosphamide (300 mg/kg i.p.),
and almost completely inhibited these behaviors at the highest dose
tested in both WT and σ1-KO mice (Fig. 7B).
Cyclophosphamide treatment (10–300 mg/kg) also produced dose-
dependent mechanical hyperalgesia referred to the abdominal wall in
both WT and σ1-KO mice (Fig. 8). The reduction in the mechanical pain
threshold induced by cyclophosphamide was nonsignificantly different
between WT and σ1-KO mice, and the lowest threshold was seen at a
dose of 100 mg/kg in both genotypes (Fig. 8); we therefore used this
dose for subsequent pharmacological experiments.
The referred mechanical hyperalgesia induced by cyclopho-
sphamide (100 mg/kg i.p.) was dose-dependently inhibited by the ad-
ministration of σ1 antagonists in WT mice (Fig. 9A). The highest doses
of all σ1 antagonists tested (BD-1063, S1RA and NE-100) in WT mice
produced mechanical threshold values that were close to the thresholds
obtained in cyclophosphamide solvent-treated animals (0.83±0.03 g)
(Fig. 9A). In contrast, all three σ1-R antagonists were devoid of effect in
σ1-KO animals (Fig. 9A). The administration of morphine (0.5–4 mg/kg
s.c.) dose-dependently reversed the referred mechanical hyperalgesia
produced by cyclophosphamide (100 mg/kg i.p.) in WT animals
(Fig. 9B). Interestingly, morphine treatment not only fully reversed
mechanical hyperalgesia but also produced an analgesic effect (me-
chanical threshold values above those in cyclophosphamide solvent-
treated animals) at doses greater than 4 mg/kg in WT mice (Fig. 9B).
Morphine also dose-dependently inhibited cyclophosphamide-induced
hyperalgesia and produced analgesia in σ1-KO mice (Fig. 9B), although
the dose-response curve was shifted to the left in these animals in
comparison to the curve obtained in WT mice (Fig. 9B).
3.5. Effect of treatment with σ1-R antagonists and morphine on
cyclophosphamide-induced enhancement of myeloperoxidase activity
To determine whether drug treatment modified the enhancement of
MPO activity induced by cyclophosphamide (300 mg/kg) in the urinary
bladder, we tested the effect of σ1-R antagonists and morphine on this
variable. Treatment of WT animals with BD-1063, S1RA or NE-100 (64,
128 and 64 mg/kg, respectively) produced a significant reduction in the
cyclophosphamide-induced increase in MPO activity in WT animals,
Fig. 1. Expression of σ1 receptor in the human
and mouse urinary bladder. Immunostaining
for σ1 receptors (brown) was found in the ur-
othelium of wild-type (WT) mice (A), but not in
σ1 receptor knockout (σ1-KO) mice (B).
Immunostaining was also found in human ur-
inary bladder sections incubated with the σ1
receptor antibody (C), but not when the pri-
mary σ1 antibody was omitted (D). The σ1 re-
ceptor antibody was identified with the Ultra
Vision Quanto™ peroxidase kit after heat-in-
duced antigenic unmasking and endogenous
peroxidase blockade. Sections were counter-
stained with Mayer’s hematoxylin. Scale bar
100 μm.
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but was devoid of effect in σ1-KO mice (Fig. 10A). In contrast, treatment
with the dose of morphine (16 mg/kg s.c.) that produced maximum
reversion of cyclophosphamide-induced pain behaviors and referred
mechanical hyperalgesia did not significantly affect the cyclopho-
sphamide-induced increase in MPO activity in either WT or σ1-KO mice
(Fig. 10B).
4. Discussion
This study reports, to the best of our knowledge, the first evidence of
the presence of a new receptor (σ1-R) in the human and mouse urinary
bladder, and documents the functional role of this receptor in the
biochemical, histopathological and behavioral manifestations of cy-
clophosphamide-induced cystitis by comparing responses in WT and σ1-
KO mice. Our findings also show that σ1-R antagonists ameliorate the
manifestations of cystitis, and therefore suggest that σ1-R may represent
a new drug target for the treatment of urological diseases.
We identified σ1-R in the urinary bladder with western blotting and
immunohistochemical techniques. The σ1-R signal was absent in σ1-KO
Fig. 2. Expression of σ1 receptor in the urinary bladder of control and cyclo-
phosphamide-treated wild-type (WT) and σ1 receptor knockout (σ1-KO) mice.
(A) Representative immunoblots for σ1 receptor detected in the urinary bladder
of control (0), WT and σ1-KO mice, and at 1, 3 or 5 h (1, 3, 5) after treatment
with cyclophosphamide (300 mg/kg i.p.) in both groups of experimental ani-
mals. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the
loading control. The migration positions of molecular mass standards (in kDa)
are shown at the right of the gels. (B) Quantification of immunoblotting for σ1
receptor in WT and σ1-KO mice. Each bar and vertical line represent the
mean± SEM (standard error of the mean) of the densitometric values obtained
in 8 animals. The σ1 receptor band intensities were relativized to those of their
corresponding GAPDH loading control bands. Note that no σ1 receptor ex-
pression was found in samples from σ1-KO mice.
Fig. 3. Myeloperoxidase activity (MPO) in the urinary bladder of control and
cyclophosphamide-treated wild-type (WT) and σ1 receptor knockout (σ1-KO)
mice. Urinary bladder MPO activity was measured 5 h after the i.p. injection of
cyclophosphamide (10–300 mg/kg) or its solvent (0). Each bar and vertical line
represent the mean± SEM of the values obtained in 5 to 7 animals. Statistically
significant differences between the values obtained in cyclophosphamide-
treated and control animals: *p<0.05, **p<0.01; and between the values
obtained in WT and σ1-KO mice at the same dose of cyclophosphamide:
##p<0.01 (two-way ANOVA followed by Bonferroni test).
Fig. 4. Total extracellular signal-regulated kinases 1/2 (ERK1/2) and phos-
phorylated ERK1/2 (pERK1/2) in the urinary bladder of control and cyclo-
phosphamide-treated wild-type (WT) and σ1 receptor knockout (σ1-KO) mice.
(A and B) Representative immunoblots for urinary bladder total ERK1/2 and
pERK1/2. In both cases, bladders were obtained from control animals (0) and at
1, 3 or 5 h (1, 3, 5) after treatment with cyclophosphamide (300 mg/kg i.p.).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the loading
control. The migration positions of molecular mass standards (in kDa) are
shown at the right of the gels. (C) Quantification of immunoblotting for pERK1/
2 in WT and σ1-KO mice. The pERK1/2 band intensities were relativized to
those of their corresponding loading control GAPDH bands. Each bar and ver-
tical line represent the mean±SEM of the values obtained in 5 to 7 animals.
Statistically significant differences between the values obtained in cyclopho-
sphamide-treated and control animals: **p<0.01; and between the values
obtained in WT and σ1-KO mice at different times after cyclophosphamide in-
jection: #p<0.05 (two-way ANOVA followed by Bonferroni test).
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animals, which indicates that it was specifically due to antibody
binding to the σ1-R protein in both techniques. The western blot results
are fully consistent with a previous study in nervous tissue [15], and
identified a band with a molecular weight (25 kDa) that matches the
expected molecular weight of the cloned σ1-R [6]. This receptor was
concentrated in the urothelium of the human and mouse urinary
bladder. This tissue is important for bladder function, is affected in a
number of bladder disorders, and expresses many receptors and chan-
nels similar to those in primary afferent sensory neurons [12]. Inter-
estingly, σ1-R is present at high densities in the dorsal root ganglia
[13–15], which further supports this similarity.
Two previously identified biochemical markers of chemically in-
duced cystitis are the enhancement of MPO activity [18,19,30,34] and
of pERK1/2 expression [20,35] in the urinary bladder. We confirmed
that cyclophosphamide treatment increased the levels of both markers
in the WT mouse urinary bladder, and found that the increase was
smaller in σ1-KO mice, which suggests that σ1-R is necessary for both
biochemical changes. Previous studies reported that neuropathy-in-
duced enhancement of spinal cord pERK1/2 expression was also
reduced in σ1-KO animals [9,36], which suggests that σ1-R regulates
ERK1/2 activation in several tissues and pathological pain models. The
enhancement of urinary bladder MPO activity is an index of neutrophil
infiltration [19,30,34], and this activity was reduced not only in σ1-KO
mice, but also in WT animals treated with σ1-R antagonists. These re-
sults indirectly indicate that σ1-R modulates neutrophil infiltration.
This effect may be related to the ability of σ1-R to regulate the ex-
pression of activated leucocyte cell adhesion molecule (ALCAM) [37],
an immunoglobulin involved in the transendothelial migration of
neutrophils [38]. Cyclophosphamide-induced cystitis increases the le-
vels of cytokines TNFα and interleukin-1β in the urinary bladder [18].
Interestingly, previous studies in different models of non-visceral pain
(bone cancer, spinal cord contusion and osteoarthritis) reported that σ1-
R antagonism inhibited TNFα and interleukin-1β production in the
spinal cord [39–41]. These findings suggest the hypothesis that at least
part of the effects of σ1-R antagonism on cyclophosphamide-induced
cystitis may also be related to the inhibition of cytokine production in
the bladder. Further studies should be done to confirm or rule out this
hypothesis.
Fig. 5. Histological analysis of cyclopho-
sphamide-induced urinary bladder alterations
in wild-type (WT) and σ1-knockout (σ1-KO)
mice. (A) Photomicrographs of hematox-
ylin–eosin-stained urinary bladders re-
presentative of solvent-treated (control) mice
and cyclophosphamide-treated (300 mg/kg
i.p., CYP 300) WT and σ1-KO mice. Urinary
bladders were obtained 5 h after treatment.
Scale bar 500 μm. (B) Quantification of edema
located in the lamina propria (relativized to
the total area of the urinary bladder section) in
cyclophosphamide-treated WT and σ1-KO
mice. (C) (Left) Detail from A (CYP 300, WT
mice) showing an area of hemorrhage (arrow-
head) and urothelial desquamation (arrow).
Scale bar 100 μm. (Right) Number of areas of
hemorrhage and urothelial desquamation in
bladders of WT and σ1-KO mice treated with
cyclophosphamide. (B and C) Each bar and
vertical line represent the mean± SEM of va-
lues obtained in 8 animals. Statistically sig-
nificant differences between the values ob-
tained in WT and σ1-KO animals: #p<0.05;
##p<0.01 (Student’s t test).
Fig. 6. Pain-related behaviors induced by cy-
clophosphamide in wild-type (WT) and σ1 re-
ceptor knockout (σ1-KO) mice. (A) Values of
total pain behavioral scores at different doses
of cyclophosphamide (10–300 mg/kg i.p.) or
its solvent (0) in WT and σ1-KO mice. (B) Time
course of pain-related behavioral scores after
the i.p. administration of cyclophosphamide
(CYP 300 mg/kg) or its solvent. Pain-related
behavioral responses were recorded at 30-min
intervals during the 4-h observation period
after the injection of cyclophosphamide or its
solvent. (A and B) Each point or bar and ver-
tical line represent the mean±SEM of values
obtained in 10 to 12 animals. Statistically sig-
nificant differences between the values ob-
tained in cyclophosphamide- and solvent-
treated animals: *p<0.05; **p<0.01; and
between the values obtained in WT and σ1-KO
animals: ##p<0.01 (two-way ANOVA fol-
lowed by Bonferroni test).
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Cyclophosphamide-induced cystitis also produces profound changes
in urinary bladder histology, with edema, hemorrhage and urothelial
desquamation [18,19,34]. All of these changes were observed in WT
mice but were attenuated in σ1-KO animals, which further supports the
functional relevance of urinary bladder σ1-R in the modulation of cy-
stitis manifestations. These results also offer an alternative explanation
for the lower MPO increase produced by cyclophosphamide in σ1-KO
animals, which may be indirectly due to the less severe bladder lesions
induced by cyclophosphamide in these animals, and the consequently
lower neutrophil infiltration.
The inhibition of σ1-R function by σ1-R antagonists in WT mice or by
σ1-R genetic deletion in σ1-KO mice reduced the behavioral manifes-
tations of pain induced by cyclophosphamide. However, σ1-R antago-
nists did not reverse the effect of cyclophosphamide in σ1-KO mice,
which indicates that the effect of these drugs was due to their specific
interaction with σ1-R. Previous studies found similar results with the
pharmacological and genetic inhibition of σ1-R function in models of
chemically-induced visceral (intracolonic capsaicin) [32] and somatic
(intraplantar formalin) pain [8,42]; however, the inhibition of σ1-R
function did not modify acute nociceptive pain induced by thermal or
mechanical stimuli [26,36,43]. These results point to differences be-
tween the underlying mechanisms of pain depending on the type of
painful stimulus, and support the need for additional studies to evaluate
the role of σ1-R function in models of urological pain induced by non-
chemical stimuli. The acute administration of σ1-R antagonists dose-
dependently inhibited referred mechanical hyperalgesia in WT mice,
but not in σ1-KO animals. These results are consistent with those of
previous studies of mechanical hypersensitivity in models of somatic
[9–11,26,36,44] and visceral (intestinal) [32] pain, and suggest that σ1-
R plays a key role in pain-induced mechanical hypersensitivity. Cy-
clophosphamide-induced referred mechanical hyperalgesia is related to
astrocytic activation in the spinal cord [45], and σ1-R antagonists are
known to inhibit this activation in models of neuropathic pain [44,46].
These findings suggest the hypothesis that the antihyperalgesic effect of
σ1-R antagonists reported here may be related to this phenomenon.
Interestingly, cyclophosphamide-induced referred hyperalgesia was
similar in WT and σ1-KO mice, which suggests that σ1-KO animals de-
velop compensatory mechanisms to express mechanical hypersensi-
tivity. Previous studies in another model of visceral pain reported si-
milar results [32]; however, the mechanical hypersensitivity observed
in several models of somatic pain was reported to be markedly reduced
or abolished in σ1-KO mice [9,11,26,36,47], which suggests that the
mechanisms underlying somatic and visceral mechanical hypersensi-
tivity are different.
Pain and mechanical hypersensitivity are relevant in several human
urinary bladder disorders [2,3,48,49]. Because σ1-R antagonists inhibit
the manifestations of cystitis in mice, and because σ1-R are distributed
similarly in the human and mouse urinary bladder, σ1-R may offer a
new drug target for the treatment of cystitis in humans. In particular,
S1RA is a highly selective σ1-R antagonist [29], is well tolerated in
humans [50], and is able to reduce neuropathic pain induced by ox-
aliplatin in patients with colorectal cancer [51]. Therefore, it may be a
potentially attractive drug for testing in human urinary bladder dis-
orders for which no adequate treatment is currently available.
It was reported previously that morphine inhibits spontaneous pain-
related behaviors and referred mechanical hyperalgesia, but does not
reduce the inflammatory response in the urinary bladder induced by
cyclophosphamide in rats [52,53]. Our results are consistent with these
findings: we found a dose-dependent reduction in pain-related beha-
viors and referred mechanical hyperalgesia, but no effect on the
Fig. 7. Effects of treatment with σ1 receptor
antagonists (BD-1063, S1RA or NE-100) or
morphine on pain-related behaviors evoked by
cyclophosphamide in wild-type (WT) and σ1
receptor knockout (σ1-KO) mice. The σ1 re-
ceptor antagonist (A), morphine (B), or their
solvent (saline, 0) was injected s.c. 120 min
after the i.p. administration of cyclopho-
sphamide (300 mg/kg), i.e. when the pain be-
havior was clearly established. Pain-related
behavioral responses were recorded at 30-min
intervals during the 150- to 240-min observa-
tion period after cyclophosphamide injection.
Each bar and vertical line represent the
mean±SEM of values obtained in 10 to 12
animals. Statistically significant differences
between the values obtained in mice treated
with the drug or saline: **p<0.01 (one-way
ANOVA followed by Bonferroni test). Note that
σ1 receptor antagonists had no effect in σ1-KO
mice, whereas morphine reduced pain-related
behaviors in both WT and σ1-KO mice.
Fig. 8. Referred mechanical hyperalgesia induced in the abdominal wall by
cyclophosphamide treatment in wild-type (WT) and σ1 receptor knockout (σ1-
KO) mice. The referred mechanical hyperalgesia (evaluated by stimulation of
the abdomen with von Frey filaments and expressed as the threshold force that
produced 50 % of the responses) was measured 240 min after the i.p. admin-
istration of different doses of cyclophosphamide (10–300 mg/kg) or its solvent
(0). Each bar and vertical line represent the mean±SEM of values obtained in
10 to 12 animals. Statistically significant differences between the values ob-
tained in cyclophosphamide- and solvent-treated animals: **p<0.01. No sig-
nificant differences were found between the values obtained in WT and σ1-KO
mice (two-way ANOVA followed by Bonferroni test).
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increase in urinary bladder MPO induced by cyclophosphamide in mice.
Taken together, these results suggest that morphine produces an an-
algesic effect without reducing urinary bladder inflammation in rodent
models of cystitis. The inhibition by morphine of cyclophosphamide-
induced pain and mechanical hypersensitivity was greater in σ1-KO
than in WT mice. These results are consistent with those of previous
studies in models of somatic and visceral pain [14,15,32,42,54]. In-
terestingly, it has been shown that the intravesical administration of
morphine, at doses that do not produce a relevant concentration of this
opioid in blood, induces analgesia after bladder surgery in humans
[55], which suggest that it exerts this effect through peripheral opioid
receptors located in the urinary bladder. We previously demonstrated
that peripheral σ1-R modulates the peripheral analgesic effects of μ-
opioid agonists in models of somatic pain [14,15,43]; therefore it could
be hypothesized that a similar mechanism may be involved in the po-
tentiation of morphine analgesia in the model of cyclophosphamide-
induced cystitis tested here. Further studies are necessary to test this
hypothesis. The inhibition of σ1-R function increases the analgesic ef-
fects of morphine and other opioid agonists without increasing their
side effects [15,42,54,56]. Because opioid agonists are used to treat
several urological disorders [57–59], it is tempting to hypothesize that
the association of σ1-R antagonists to opioid agonists might offer a
potentially interesting approach for the treatment of these disorders. In
this connection, unpublished results from our group showed that σ1-R
antagonists increased the analgesia induced not only by morphine but
also by other opioids in cyclophosphamide-induced cystitis in mice
(manuscript in preparation).
In summary, this study shows that σ1-R is present in the human and
mouse urinary bladder urothelium, and demonstrates that σ1-R plays a
functional role in the mechanisms underlying cyclophosphamide-in-
duced cystitis in mice. We suggest that σ1-R may represent a new drug
target for the treatment of urological disorders.
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